2,086 reports of this reaction
1.4% of all PEGFILGRASTIM reports
#18 most reported adverse reaction
DRUG DOSE OMISSION BY DEVICE is the #18 most commonly reported adverse reaction for PEGFILGRASTIM, manufactured by Amgen, Inc. There are 2,086 FDA adverse event reports linking PEGFILGRASTIM to DRUG DOSE OMISSION BY DEVICE. This represents approximately 1.4% of all 146,341 adverse event reports for this drug.
Patients taking PEGFILGRASTIM who experience drug dose omission by device should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG DOSE OMISSION BY DEVICE is a less commonly reported adverse event for PEGFILGRASTIM, but still significant enough to appear in the safety profile.
In addition to drug dose omission by device, the following adverse reactions have been reported for PEGFILGRASTIM:
The following drugs have also been linked to drug dose omission by device in FDA adverse event reports:
DRUG DOSE OMISSION BY DEVICE has been reported as an adverse event in 2,086 FDA reports for PEGFILGRASTIM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG DOSE OMISSION BY DEVICE accounts for approximately 1.4% of all adverse event reports for PEGFILGRASTIM, making it a notable side effect.
If you experience drug dose omission by device while taking PEGFILGRASTIM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.